The firm said that its multiplex point-of-care test uses 10 microliters of blood from a fingertip and provides quantitative results in about 15 minutes.
The VioOne HIV supplemental assay is for confirming and differentiating individual antibodies directed to various gene products of HIV-1 and HIV-2.
Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.
The firm said that its HSV and varicella-zoster virus assay delivers answers for related herpes conditions in about an hour.
The firm is developing a multipanel test and an antibiotic resistance panel to augment its recently CE marked chlamydia and gonorrhea assay.
Roche said that the test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting resistance to the antibiotics rifampicin and isoniazid.
The company said that the DxA 5000 reduces the number of required manual steps and can shorten the preanalytical processing time by up to 73 percent.
The Swiss company's new immunohematology microarray runs on the company's MosaiQ high-throughput automated platform for blood transfusion testing.
The firm said that its point-of-care test delivers laboratory-quality results in about 30 minutes and could be used in the home and other settings.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.